Advancements in the Management of R/R AML: ASH 2024 - Episode 7
MRD Testing and the Role of Revumenib in Treatment Response
Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.
Video content above is prompted by the following:
- Dr. LeBlanc to ask GROUP: What role does MRD testing play within AML?
- Dr. LeBlanc to ask Dr. Mannis: Briefly comment on the key findings presented for revumenib from the ALLG AMLM26 INTERCEPT study.(Loo, S, et al. ASH 2024. Oral Abstract 223, Session: 619 or pg. 11)
- Dr. LeBlanc to ask Dr. Thirman: How does the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML inform the future of MRD-guided treatment strategies, and what might this mean for integrating menin inhibitors into standard AML relapse prevention protocols?
Related Content:
